Aerospace Nanotechnology Market Current Trends, Swot Analysis, Business Overview and Forecast by 2028 | Key Players: Airbus, Glonatech, Flight Shield,…

Posted on August 8, 2020 by Danzig

A recent report published by QMI on the aerospace nanotechnology market is a detailed assessment of the most important market dynamics. After carrying out a thorough research of aerospace nanotechnology market historical as well as current growth parameters, business expectations for growth are obtained with utmost precision.

Get Sample Copy of This Report @https://www.quincemarketinsights.com/request-sample-62977?utm_source=PF/SG

The study identifies specific and important factors affecting the market for aerospace nanotechnology during the forecast period. It can enable companies investing in aerospace nanotechnology market to change their production and marketing strategies in order to envisage maximum growth.

According to the report, the aerospace nanotechnology market has been segmented by product type (nanomaterials, nanotools, nanodevices), by end user (aircraft parts, fuselage structure, aero engine parts, aircraft electronic communication system, other).

Insights about regional distribution of market:The market has been segmented in major regions to understand the global development and demand patterns of this market. For aerospace nanotechnology market, the segments by region are North America, Asia Pacific, Western Europe, Eastern Europe, Middle East, and Rest of the World. During the forecast period, North America, Asia Pacific and Western Europe are expected to be major regions on the aerospace nanotechnology market.

North America and Western Europe have been dominant players in this market with the presence of major companies which have a strong infrastructure to boost aerospace &defense sector. In addition, some of the major countries like the US, France, UK, and Canada has been global exporters of aerospace &defense technologies due to established research & development centers, and others. Also, some of the major companies operating in aerospace nanotechnology market are headquartered in these regions.

The Asia Pacific region is estimated to register fastest growing aerospace nanotechnology market since some of the major economies like China, India, and South Korea are present in the region. In recent decades, these countries have witnessed strong government spending on defense infrastructure, as well as promoting air transport and space research. During the forecast period, the Middle East region is estimated to be a potential region for aerospace nanotechnology market in the aerospace and defense sector. It is estimated that Eastern Europe will have stable demand during the forecast period. Also, the rest of the world is expected to be an emerging market with increasing demand.

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:

1. Airbus2. Glonatech3. Flight Shield4. Lockheed Martin5. Lufthansa Technik, tripleO Performance Solution6. Zyvex Technologies7. CHOOSE NanoTech8. General Nano9. HR TOUGHGUARD10. Metamaterial Technologies.

Make an Inquiry for purchasing this Report @https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-62977?utm_source=PF/SG

Market Segmentation:By Product Type:o Nanomaterialso Nanotoolso Nanodevices

By End User:o Aircraft Partso Fuselage Structureo Aero Engine Partso Aircraft Electronic Communication Systemo Other

By Region:North Americao North America, by Countryo USo Canadao Mexicoo North America, by Product Typeo North America, by End User

Western Europeo Western Europe, by Countryo Germanyo UKo Franceo Italyo Spaino The Netherlandso Rest of Western Europeo Western Europe, by Product Typeo Western Europe, by End User

Asia Pacifico Asia Pacific, by Countryo Chinao Indiao Japano South Koreao Australiao Indonesiao Rest of Asia Pacifico Asia Pacific, by Product Typeo Asia Pacific, by End User

Eastern Europeo Eastern Europe, by Countryo Russiao Turkeyo Rest of Eastern Europeo Eastern Europe, by Product Typeo Eastern Europe, by End User

Middle Easto Middle East, by Countryo UAEo Saudi Arabiao Qataro Irano Rest of Middle Easto Middle East, by Product Typeo Middle East, by End User

Rest of the Worldo Rest of the World, by Countryo South Americao Africao Rest of the World, Product Typeo Rest of the World, by End User

Objectives of this report:o To estimate the market size for the aerospace nanotechnology market on a regional and global basis.o To identify major segments in the aerospace nanotechnology market and evaluate their market shares and demand.

o To provide a competitive scenario for the aerospace nanotechnology market with major developments observed by key companies in the historic years.o To evaluate key factors governing the dynamics of the aerospace nanotechnology market and their potential gravity during the forecast period.

Reasons to Buy This Report:o Offers unique insights into the decision-making process for every possible segment that aids in strategic decision making.o Market size estimate of regionally and internationally focused aerospace nanotechnology market.o Unique research methodology based on the dynamics of the aerospace nanotechnology market.o Identification of major companies operating in the industry with key strategies adopted in recent yearso Exhaustive scope to help each stakeholder across the value chain of the aerospace nanotechnology market.

Customization:This study is customized to meet your specific requirements:o By Segmento By Sub-segmento By Region/Countryo Product Specific Competitive Analysis

Contact:

Quince Market InsightsAjay D. (Knowledge Partner)Office No- A109Pune, Maharashtra 411028Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 144 439 0986Email:[emailprotected]Web:www.quincemarketinsights.com

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Read the original post:

Aerospace Nanotechnology Market Current Trends, Swot Analysis, Business Overview and Forecast by 2028 | Key Players: Airbus, Glonatech, Flight Shield,...

How studying genetics and lifestyle can shape a healthier MENA region – The European Sting

Posted on August 8, 2020 by Danzig

(Credit: Unsplash)

This article is brought to you thanks to the collaboration ofThe European Stingwith theWorld Economic Forum.

Author: Habiba Al Alsafar, Associate Professor, Department of Biomedical Engineering, Khalifa University of Science, Technology and Research (KUSTAR) & Elizabeth ODay, Founder and Chief Executive Officer, Olaris Inc

Diagnosing diseases can be complex, because illness is not a fixed state and has to be considered in context. We may be born with factors that predispose us to disease, but our lifestyle dictates if and when undesirable symptoms will manifest themselves.

For example, our middle-eastern forefathers were relatively healthier than us because of a nomadic lifestyle which was considerably more active. Our genes have remained unchanged in our recent history, yet the prevalence of a number of lifestyle diseases such as diabetes and obesity has risen in contemporary middle eastern countries. This is in part due to a shift towards more sedentary lifestyles. The environment and our lifestyles are working in concert with inherent elements (that is, the products of our genome) to contribute to the status of our health.

The intersection of genetics and lifestyle choices is playing an increasingly significant role in managing the health of middle eastern populations. The prevalence of chronic disease, in particular diabetes and its associated complications, is alarmingly high throughout the Gulf States. According to the 2017 report from the International Diabetes Federation, 11% of the population in the Middle East and North Africa (MENA) region has diabetes. Disturbingly, the prevalence is higher in the population of countries like the United Arab Emirates (UAE), where 19.3% of those between the ages of 20 and 79 have type-2 diabetes. A number of major co-morbidities are linked to diabetes and of these, cardiovascular disease is the highest cause of mortality in the UAE, accounting for 40% of mortalities. Non-communicable diseases (NCDs) in total are responsible for 77% of all deaths in the UAE. Both men and women are dying prematurely, resulting in a profound impact on families specifically and the community on the whole. The impact is not only limiting progress and development of the nation, it has a bearing on government spending as treating end-stage disease carries significant costs.

To manage the health of a nation we must shift our attention to examine both genetics and the impact of lifestyle choices.

A recent audit of the worlds genomic data showed that the predominant genomes in public databases belong to Europeans (81%), while only 0.08% of the genome inventory represents ancestries from Arab and Middle Eastern populations. The genomes of people of Asian and African ancestries at 14% and 3% respectively were also relatively low.

A breakdown of non-European genomic data samples

Image: Nature

As alluded to above, the genome is a key part of the puzzle that is required for understanding disease within a population. Efforts are clearly being made to increase our understanding of the genomes of people with middle eastern ancestries and the genomes from efforts in Kuwait, Qatar and the UAE are now available. It comes at a time when sequencing costs have plummeted and are no longer prohibitive. Innovation in genome sequencing technologies does not appear to be slowing, and continued reductions in the cost can be expected.

We have and continue to propose the need to develop collaborative linkages: locally, throughout the region and internationally. Collaboration needs to be encouraged and should involve all sectors of healthcare, including practicing physicians and paramedics, policy-makers and research scientists. It is only through coordinated efforts throughout the region that patients will ultimately be provided with the information that will enable individuals, and their care providers, to make informed decisions about their health and wellbeing. Importantly, strong local leadership is required, because as the Portuguese writer and Nobel laureate Jos Saramago put it: If you dont write your books, nobody else will do it for you. No one else has lived your life.

NCDs account for 77% of all deaths in UAE

Image: WHO

The paradigm shift in healthcare that personalized or precision medicine customizing medical treatment to the individual characteristics, needs and preferences of a patient during all stages of care represents has been made possible through the availability of large datasets compiled by healthcare systems, technological advancements in next-generation genome sequencing and the development of proper analytical tools to identify relationships in vast datasets.

This is a systems biology approach that uses genome, phenome and microbiome data to quantify the wellness of an individual and to provide indicators of their impending disease state. The Pioneer 100 Wellness Project (P100) was a longitudinal study in the US designed to test this approach. It that was conceived on the rationale that as the scale of personal data increases with the convergence of advances in electronic health records sets, big data analysis, individual measurement devices, and consumer-activated social networks, it would be possible to define early warning signs for human diseases. Although the opportunities for observing health transitions in P100 were limited, the results were sufficiently compelling that it has justified refinements for an extended study involving a larger population of more than 100,000 individuals.

Health and healthcareHow is the World Economic Forum bringing data-driven healthcare to life?

The application of precision medicine to save and improve lives relies on good-quality, easily-accessible data on everything from our DNA to lifestyle and environmental factors. The opposite to a one-size-fits-all healthcare system, it has vast, untapped potential to transform the treatment and prediction of rare diseasesand disease in general.

But there is no global governance framework for such data and no common data portal. This is a problem that contributes to the premature deaths of hundreds of millions of rare-disease patients worldwide.

The World Economic Forums Breaking Barriers to Health Data Governance initiative is focused on creating, testing and growing a framework to support effective and responsible access across borders to sensitive health data for the treatment and diagnosis of rare diseases.

The data will be shared via a federated data system: a decentralized approach that allows different institutions to access each others data without that data ever leaving the organization it originated from. This is done via an application programming interface and strikes a balance between simply pooling data (posing security concerns) and limiting access completely.

The project is a collaboration between entities in the UK (Genomics England), Australia (Australian Genomics Health Alliance), Canada (Genomics4RD), and the US (Intermountain Healthcare).

Although currently viewed as a radical shift, preemptive measures have been proposed since the turn of the last century. In 1903, motivated by concerns about the healthcare of his time, Thomas Edison said: The doctor of the future will give no medicine, but will interest his patient in the care of the human frame, in diet and in the cause and prevention of disease. Through the more than 100 years since this statement, preventative strategies have taken hold in some areas of medicine (such as immunization), but there is more to do. In the words of the 11th century Persian physician and polymath Avicenna, There are no incurable diseases only the lack of will. There are no worthless herbs only the lack of knowledge. There is certainly no lack of will, and our knowledge is only expanding.

Therefore, the opportunity to apply personal medicine practices in the UAE to prevent or delay the onset of disease will have substantial social and economic impacts. The American physcian and systems biologist Dr Leroy Hood has predicted that the wellness and prevention market will outgrow the healthcare market, in part due to economic modelling which suggests that the reactive therapeutic route is unsustainable for ageing populations. The time to act is now.

Read the original:

How studying genetics and lifestyle can shape a healthier MENA region - The European Sting

Immatics Extends Cell Therapy Manufacturing Collaboration with UTHealth – marketscreener.com

Posted on August 8, 2020 by Danzig

Houston, Texas, Aug. 06, 2020 (GLOBE NEWSWIRE) --

Houston, Texas, August 6, 2020 Immatics N.V. (NASDAQ: IMTX; Immatics), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today announced the extension of its cell therapy manufacturing collaboration with The University of Texas Health Science Center at Houston (UTHealth), in Houston, Texas. The continued collaboration grants Immatics access to UTHealths state-of-the-art cGMP manufacturing infrastructure at the Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory, enabling continued production and supply of Immatics specialized, cell-based product candidates for testing in multiple clinical trials. Maximum capacity of the facility is anticipated at 48 ACTengine T cell products per month. The new agreement will run until the end of 2024. Under the agreement, UTHealth will provide Immatics with exclusive access to three cGMP suites and support areas for the manufacturing of various Adoptive Cell Therapy (ACT) products. Therapeutic T cell production will be carried out by Immatics manufacturing personnel and will be supported by a UTHealth-Immatics joint quality team.

Steffen Walter, Ph.D., Chief Technology Officer at Immatics, commented: During the last five years, we have established a strong and productive partnership with UTHealth that has enabled the initiation of four ongoing clinical trials. As we remain focused on the development of our clinical pipeline, this extension of our collaboration with UTHealth will fulfill Immatics manufacturing needs for our early-stage ACT clinical programs for the next four years. Being able to rely on a partner with profound cell therapy expertise who is familiar with our technologies and can support cGMP cell therapy production is critical to ensuring the advancement of our clinical trials. We look forward to continuing this fruitful collaboration with the experts at UTHealth.

Fabio Triolo, D.d.R., M.Phil., Ph.D., The Clare A. Glassell Distinguished Chair and Director of the Cellular Therapy Core at UTHealth, added: Signing the extended contract with Immatics fits into our strategy at UTHealth of supporting the development of new treatments for patients in need. We therefore look forward to continuing our collaboration and further leveraging the potential of our manufacturing capabilities.

About Immatics ACT ProgramsACTengine is a personalized approach in which the patients own T cells are genetically modified to express a novel proprietary TCR cognate to one of Immatics proprietary cancer targets which are then reinfused back into the patient. Immatics latest proprietary ACTengine manufacturing processes are designed to generate cell product candidates within a short six day manufacturing window and to deliver highly proliferative T cells, with the capability to infiltrate the patients tumor and function in a challenging solid tumor microenvironment. The process is designed to rapidly produce younger, better-persisting T cells capable of serial killing tumor cells in vitro. Immatics is further advancing the ACT concept beyond individualized manufacturing with its product class ACTallo which is being developed to generate off-the-shelf cellular therapies.

More information on the clinical trials can be found at the following links: https://immatics.com/clinical-programs/ and https://clinicaltrials.gov/.

- ENDS -Notes to Editors

About ImmaticsImmatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.

For regular updates about Immatics, visit http://www.immatics.com. You can also follow us on Twitter and LinkedIn.

About UTHealthEstablished in 1972 by The University of Texas System Board of Regents, The University of Texas Health Science Center at Houston (UTHealth) is Houstons Health University and Texas resource for health care education, innovation, scientific discovery and excellence in patient care. The most comprehensive academic health center in the UT System and the U.S. Gulf Coast region, UTHealth is home to Jane and Robert Cizik School of Nursing, John P. and Kathrine G. McGovern Medical School and schools of biomedical informatics, biomedical sciences, dentistry and public health. UTHealth includes The University of Texas Harris County Psychiatric Center, as well as the growing clinical practices UT Physicians, UT Dentists and UT Health Services. The universitys primary teaching hospitals are Memorial Hermann-Texas Medical Center, Childrens Memorial Hermann Hospital and Harris Health Lyndon B. Johnson Hospital. For more information, visit http://www.uth.edu.

About the Evelyn H. Griffin Stem Cell Therapeutics Research LaboratoryThe Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory, which is part of the Cellular Therapy Core at UTHealth, has been Immatics manufacturing partner since 2015. The site is a U.S. Food and Drug Administration (FDA)-registered and inspected cGMP facility that has received accreditation from the Foundation for Accreditation of Cellular Therapy (FACT) as well as certification from the Clinical Laboratory Improvement Amendment (CLIA) and the College of American Pathologists (CAP).

Forward-Looking StatementsCertain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or Immatics future financial or operating performance. For example, statements concerning the timing of product candidates and Immatics focus on partnerships to advance its strategy are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as may, should, expect, intend, will, estimate, anticipate, believe, predict, potential or continue, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in filings with the Securities and Exchange Commission (SEC). Nothing in this presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Immatics undertakes no duty to update these forward-looking statements.

Go here to read the rest:

Immatics Extends Cell Therapy Manufacturing Collaboration with UTHealth - marketscreener.com

New Report: Regenerative Medicine & Advanced Therapies Sector Thriving Despite COVID-19 – GlobeNewswire

Posted on August 8, 2020 by Danzig

Cell, Gene & Tissue-Based Therapy Developers Poised to Break Year-Over-Year Global Financing Records

WASHINGTON, D.C., Aug. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, today announces the publication of its H1 2020 Global Sector Report, Innovation in the Time of COVID-19. The report provides an in-depth look at trends and metrics in the gene, cell, and tissue-based therapeutic sector in the midst of the pandemic.

As the voice of the sector globally, ARM regularly publishes sector data reports to showcase clinical and scientific progress, as well as advancements and remaining challenges in the policy environment surrounding cell, gene and tissue-based therapies. The report also includes updated metrics on fundraising and clinical trials from more than 1,000 therapeutic developers worldwide.

Highlights from the H1 2020 Global Sector Report include:

Janet Lambert, CEO of ARM, commented:The regenerative medicine and advanced therapy sector has shown remarkable resilience in the face of many new challenges posed by COVID-19. Most importantly, were continuing to see patients benefit from the profound therapeutic effects of both approved products and those currently in clinical development. ARM will continue to work with our membership and with policymakers in the second half of 2020 to further advance these transformative technologies. We are committed to bringing these life-changing therapies to patients in need.

This report is the latest in ARMs series of global regenerative medicine sector reports, providing up-to-date metrics on financings and the clinical landscape, as well as expert commentary on key trends and progress in the field. The full report is availableonline here, with key sector metrics and infographicsavailable here. For more information, please visitwww.alliancerm.orgor contact Kaitlyn (Donaldson) Dupont atkdonaldson@alliancerm.org.

About the Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies. ARM promotes legislative, regulatory and reimbursement initiatives to advance this innovative and transformative sector, which includes cell therapies, gene therapies and tissue-based therapies. Early products to market have demonstrated profound, durable and potentially curative benefits that are already helping thousands of patients worldwide, many of whom have no other viable treatment options. Hundreds of additional product candidates contribute to a robust pipeline of potentially life-changing regenerative medicines and advanced therapies. In its 11-year history, ARM has become the voice of the sector, representing the interests of 360+ members worldwide, including small and large companies, academic research institutions, major medical centers and patient groups. To learn more about ARM or to become a member, visithttp://www.alliancerm.org.

Impact of COVID-19 Outbreak on Canine Stem Cell Therapy Market Expected to Secure Notable Revenue Share During 2020-2026 – Research Newspaper

Posted on August 8, 2020 by Danzig

This Canine Stem Cell Therapy Market report includes worldwide topmost prime manufactures like (VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos, Vetbiologics, VetMatrix, Magellan Stem Cells, ANIMAL CELL THERAPIES, Stemcellvet) in terms of company basic information, Product Category, Sales (Volume), Revenue (Million USD), Price, Gross Margin (%), Price, Cost, Growth Rate, Import, Export, Market Share and Technological Developments. Canine Stem Cell Therapy Market report provide the COVID19 Outbreak Impact analysis of key factors influencing the growth of the Canine Stem Cell Therapy market Size (Production, Value and Consumption). In the end, the Canine Stem Cell Therapy industry report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures)of Canine Stem Cell Therapy[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2081893

Canine Stem Cell Therapy Market Report Offers Comprehensive Assessment Of 1) Executive Summary, 2) Canine Stem Cell Therapy Market Overview, 3) Key Market Trends, 4) Key Success Factors, 5) Market Demand/Consumption (Value or Size in US$ Mn) Analysis, 6) Canine Stem Cell Therapy Market Background, 7) Canine Stem Cell Therapy industry Analysis & Forecast 20202026 by Type, Application and Region, 8) Canine Stem Cell Therapy Market Structure Analysis, 9) Competition Landscape, 10) Company Share and Company Profiles, 11) Assumptions and Acronyms and, 12) Research Methodology etc.

Scope of Canine Stem Cell Therapy Market:The non-invasive stem cell obtaining procedure, augmented possibility of accomplishing high quality cells, and lower price of therapy coupled with high success rate of positive outcomes have collectively made allogeneic stem cell therapy a preference for veterinary physicians. Moreover, allogeneic stem cell therapy is 100% safe, which further supports its demand on a global level. Pet owners are identified to prefer allogeneic stem cell therapy over autologous therapy, attributed to its relatively lower costs and comparative ease of the entire procedure.

A rapidly multiplying geriatric population; increasing prevalence of chronic ailments such as cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry.

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, shipments, revenue (Million USD), price, and market share and growth rate foreach application.

Veterinary Hospitals Veterinary Clinics Veterinary Research Institutes

On the basis of product type, this report displays the shipments, revenue (Million USD), price, and market share and growth rate of each type.

Allogeneic Stem Cells Autologous Stem cells

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2081893

The report offers in-depth assessment of the growth and other aspects of the Canine Stem Cell Therapy market in important countries (regions), including:

The Following Points Are Important In Performing A Competitive Assessment of Canine Stem Cell Therapy Market:

What will make the customer buy from this operation instead of the competition?

Comparison between the products/services to the competitors products/services of Canine Stem Cell Therapy market (Features, Service, Quality, Price, Distribution, And Brand).

List the companies involved in the production of these products/services.

Describe the Canine Stem Cell Therapy market concentration (Such As Large Number of Small Players or Small Number of Large Players).

Detail the Canine Stem Cell Therapy market prevailing competitive intensity (Fierce Competition or Live and Let-Live).

Describe the competitors facile Canine Stem Cell Therapy market entry (Can the Easy Entry of Competitors Drive down Prices in the Market?)

Describe the clients competitive strategies against competitors and their products of Canine Stem Cell Therapy market(Low Cost, Niche Market, Product Differentiation, Etc.).

Contact:

ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]

Browse More Reports Visit @https://www.mytradeinsight.blogspot.com/

Continued here:

Impact of COVID-19 Outbreak on Canine Stem Cell Therapy Market Expected to Secure Notable Revenue Share During 2020-2026 - Research Newspaper

UK housing is on the agenda. How do we really build back better? – Big Issue

Posted on August 8, 2020 by Danzig

In part one of a special investigation, we consider the government's move to make it easier for developers to create not-fit-for-purpose homes in office buildings

Britain is at a housing tipping point. Our need for social housing, built well and built quickly, has never been more urgent. There is less housing stock available, there is a need to find homes for the previously homeless to meet the laudable ambition currently sounded by the authorities, and there is a growing need for affordable new homes for many others. Quality and a good place to live are key.

However, last month Westminster housing secretary Robert Jenrick announced a change in legislation making it easier for developers to convert buildings like offices into residential units, a practice largely shown to produce shoddy homes that promote overcrowding. The government says this will help us build back from the Covid-19 crisis. It leaves the situation on the horns of a dilemma. Build quickly for now, or build correctly for tomorrow?

The extension of permitted development rights (PDR) means offices, shops and warehouses in England can now not only be repurposed for housing but also demolished entirely to build homes on the land without planning permission. It means developers can sidestep minimum space standards and arent beholden to Section 106 a requirement that they contribute to the local community, whether by creating a percentage of affordable housing or injecting cash into local amenities. Instead, they submit a prior approval notice to the local authority, who can only consider limited factors such as flood risk and traffic when deciding if the project can go ahead.

The idea is that the creation of something built to fit the national standards is streamlined. But the resulting homes are tiny flats as small as 13 square metres in some cases with poor ventilation and internal windows reducing privacy. Some have no windows at all.

New rules dont take into account what we have learned about housing from the Covid-19 crisis

When the Royal Institution of Chartered Surveyors (RICS) researched the issue in 2018, it concluded that these conversions come at a cost both financially and socially. At the time one resident in a Croydon office-to-residential conversion said that their building wasnt maintained and that the large number of children living there had no access to outdoor space where they could play. Another said that because the building wasnt built with residential use in mind, there was next to no noise insulation, impacting quality of life for those living inside.

Im speechless, one resident said. How can this be allowed in a civilised country? Its so wrong. The politicians who allowed this need to come and live here. Its a total nightmare.

Just 30 per cent of the homes created through extended PDR in the past met minimum space standards nearly 80 per cent were studios or one-bed units, compared to just 37 per cent of those created using the full planning permission process.

When compared to similar developments in Glasgow conversions in Scotland and Wales must still go down the planning route homes in the Scottish city were found to be much higher quality and better maintained, and had more space for families to live in. RICS concluded that easing up office-to-residential rules was a fiscal giveaway from the state to private real estate developers.

In fact, the PDR changes contradict the governments own research. The same week Jenrick made the announcement, the Ministry of Housing, Communities and Local Government published a report blasting office-to-residential conversions created without full planning permission as seeming to create worse quality residential environments than planning permission conversions in relation to matters of health, wellbeing and quality of life.

Its a policy that appears to produce a lot of housing quickly, says RICS associate director of planning and development Tony Mulhall, but housing with question marks all over it.

What I have seen when visiting conversions like these has shocked me, he says. People are expected to live without any natural light or space to move around.

Its no good having developers approach national standards as technicalities to comply to. Those standards are about function. Homes need to work for the people living in them or they shouldnt be built.

The idea of converting office buildings to homes is something that fits in with how our towns and cities are changing, he says and its likely office space will be less in demand in the future now that companies have discovered home working to be viable. We dont always have one area for offices, another for houses like we once did. And offices are often in really handy locations. If you can live close to where you work and shop close to where you live, that makes good sense. But those buildings are often just totally unsuitable to be converted.

Its an issue developers can exploit particularly in global cities like London, he adds, where many people are desperate for homes just to get a toehold in the area. The new rules dont take into account what we have learned about housing from the Covid-19 crisis that overcrowding is a danger to public health, and that outdoor space is vital. Instead of loosening restrictions, we should be thinking about how important the addition of a balcony can be to small flats, Mulhall says. And even when done well, these conversions dont turn out cheap.

Who are these homes going to be for? Thats something that should be asked more often, he says. Many of these units go into the private rental market, sometimes earmarked as affordable housing but in practice theyre very expensive. Research into office-to-residential conversions in Leeds and Leicester found they were mostly marketed as expensive student flats, doing little to meet local housing need. And last year it emerged that some of the 210,000 children whose families were caught up in the housingcrisis were moved into unsuitable converted office blocks as temporary accommodation.

New homes created through extended PDR have an impact on cash-strapped councils, too. RICS estimated that the financial impact to Englands local authorities was a net loss of around 50m. Around 42.5m of that came from the affordable housing contributions developers would have been required to make had they gone through the planning permission process. Councils are actively opposing the governments latest changes.

Councillor David Renard, housing spokesperson for the Local Government Association, tells The Big Issue: The planning system is not a barrier to housebuilding, with nine in 10 planning applications approved by councils. It gives local communities the power to shape the area they live in and provides an effective means of balancing the interests of homeowners and their neighbours.

Taking away the right of locals to have a say about what happens in their community deprives them of the ability to define the area they live in and know best, he says. It risks giving developers the freedom to ride roughshod over local areas with communities having no way of ensuring they meet high quality standards, provide any affordable homes as part of the development or ensure supporting infrastructure such as roads, schools and health services are in place.

RICS research also showed that PDR conversions made it more difficult for councils to meet local social housing need. Yet just days after Jenrick announced the changes for developers, a Westminster housing select committee released a report urging ministers to start building 90,000 social homes a year to beat Englands broken housing system.

Go here to see the original:

UK housing is on the agenda. How do we really build back better? - Big Issue

Calyxt will license its plant gene-editing tech to other firms – Minneapolis Star Tribune

Posted on August 8, 2020 by Danzig

Calyxt, a food technology company spawned by the University of Minnesota, said this week it will offer its gene-editing technology in licensing deals to other companies.

The company whose technology is known as TALEN and uses molecular scissors to remove undesirable traits in plants had until recently focused on contracting with farmers to grow their seeds and managing the manufacture of products made from the crops.

It is now in talks with several companies to license its technology or the specific traits in plants it has developed.

It would be a competitor to the CRISPR technology thats out there, but we believe we have a little cleaner commercialization plan with TALEN than what CRISPR has, said Travis Frey, the firms chief technology officer.

One high-profile example was high-oleic soybeans, which were converted into oil by a processor in Iowa and sold under the Calyxt brand Calyno.

In its new emphasis on licensing its technology and the traits it develops, Calyxt is pivoting away from managing the processing and sale of end products like oil, Frey said.

Most of the partners were looking at are probably going to put it under their own brand, Frey said. Theyre just much better at doing that, and the other thing is it helps us get revenue. We can earn cash sooner.

The publicly traded firm, launched in 2019, said it is in the advanced stages of developing improved-digestibility alfalfa, high fiber wheat, feminized and low THC hemp for fiber, food and CBD, gluten-free and cold-tolerant oats and pulses with improved flavor and protein.

Companies that want to develop products with that technology, or with traits developed by Calyxt, will now be able to secure a license.

Based in Roseville, the company got an exclusive license in 2015 to commercialize technology developed at the Us Department of Genetics, Cell Biology and Development.

Calyxt has not turned a profit since its inception and lost $39.6 million in 2019, but gene-editing is one of the hottest topics in agriculture.

Major seed companies are still working to dig out of the public relations and regulatory quagmire of genetically modified organisms, or GMOs. Gene-editing does not add foreign DNA to plants so the resulting products are not considered to be GMOs.

Follow this link:

Calyxt will license its plant gene-editing tech to other firms - Minneapolis Star Tribune

JinkoSolar reshapes PV technology scenarios with its new N-Type Tiger Pro 610W unveiled at SNEC 2020 – PRNewswire

Posted on August 8, 2020 by Danzig

SHANGRAO, China, Aug. 7, 2020 /PRNewswire/ -- JinkoSolar Holding Co., Ltd. ("JinkoSolar" or "Company") (NYSE: JKS) one of the world's largest and most innovative module manufacturers in the world, today launched its new generation of 610W Tiger Pro High-efficiency monocrystalline TR solar module and its BIPV solutions, Building Integrated Photovoltaics product series, which will be unveiled at SNEC 2020 in Shanghai.

As a PV company that has ranked first in global modules shipments for four consecutive years, JinkoSolar has always been committed to providing global customers with high-efficiency, top quality, and extremely reliable solar modules. The key behind the success of Tiger Pro 610W is the N-Type HOT 2.0 high-efficiency cell technology, independently developed by JinkoSolar. Thanks to the introduction of new technologies, such as HOT tunneling layer passivated contact and advanced metallization, the cell efficiency has reached 24.79%, setting once again a world record for the efficiency of large area N-Type monocrystalline silicon solar cells. At the same time, the use of 78 cell design and of TR technology, which helps reduce significantly the cell gap, as well as lower the electricity cost and improve the system compatibility, represents another milestone for the PV industry in its quest for grid parity.

JinkoSolar's module series have continuously broken the conversion efficiency record, starting from 2018, JinkoSolar Eagle PERC high-efficiency monocrystalline series, with a power of 390W and a conversion efficiency of 19.8%, followed by the Tiger HOT 1.0 high-efficiency monocrystalline series delivering a power output up to 475W and a conversion efficiency of 20.87%. The newest Tiger Pro HOT2.0, high-efficiency monocrystalline series, with its maximum output of 610W and a conversion efficiency of 22.3%, is setting once again new-standards for the industry and positioning JinkoSolar far ahead from its competitors.

Moreover, thanks to the great improvements made with the smart combination "PV + Architecture", during this edition of SNEC, JinkoSolar also unveiled its first version of colored BIPV module series.With a power output of up to 550W, this product series is available in a variety of colors and levels of translucence, incorporating modern architectural aesthetics for use as a building component.

Dr. Jin Hao, CTO of JinkoSolar, commented: "Reducing costs and increasing efficiency is the goal that the industry has always been striving for. JinkoSolar has always been committed to providing global customers with high-efficiency, top quality, and extremely reliable solar modules. We will increase our investment in R&D to ensure constant innovation in our technology, improve our products performance, and ensure the highest system compatibility. This will allow us to fulfill our commitment to offer the best service to our global customers and to allow the application of our solar modules in a variety of scenarios, further empowering the solar PV industry and achieving grid parity."

About JinkoSolar Holding Co., Ltd.

JinkoSolar (NYSE: JKS) is one of the largest and most innovative solar module manufacturers in the world. JinkoSolar distributes its solar products and sells its solutions and services to a diversified international utility, commercial and residential customer base in China, the United States, Japan, Germany, the United Kingdom, Chile, South Africa, India, Mexico, Brazil, the United Arab Emirates, Italy, Spain, France, Belgium, and other countries and regions. JinkoSolar has built a vertically integrated solar product value chain, with an integrated annual capacity of 17.5 GW for mono wafers, 10.6 GW for solar cells, and 16 GW for solar modules, as of March 31, 2020.

JinkoSolar has over 15,000 employees across its 7 productions facilities globally, 14 overseas subsidiaries in Japan, South Korea, Vietnam, India, Turkey, Germany, Italy, Switzerland, United States, Mexico, Brazil, Chile and Australia, and global sales teams in China, United Kingdom, France, Spain, Bulgaria, Greece, Ukraine, Jordan, Saudi Arabia, Tunisia, Morocco, Kenya, South Africa, Costa Rica, Colombia, Panama, Kazakhstan, Malaysia, Myanmar, Sri Lanka, Thailand, Vietnam, Poland and Argentina.

To find out more, please see: http://www.jinkosolar.com

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends, "plans," "believes," "estimates" and similar statements. Among other things, the quotations from management in this press release and the Company's operations and business outlook, contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in JinkoSolar's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. Except as required by law, the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

For investor and media inquiries, please contact:

Ms. Ripple ZhangJinkoSolar Holding Co., Ltd.Tel: +86 21-5183-3105Email: [emailprotected]

SOURCE JinkoSolar Holding Co., Ltd.

http://www.jinkosolar.com

See the original post here:

JinkoSolar reshapes PV technology scenarios with its new N-Type Tiger Pro 610W unveiled at SNEC 2020 - PRNewswire

By Next Year, Will Doctors Finally Have The Technology To Fully Personalize Treatments For Lung Cancer Patients? – Forbes

Posted on August 8, 2020 by Danzig

Today, with the new risks posed by Covid, how do we provide the best care for people with non-Covid- related disease? For diagnosed cancer patients, these risks may warrant a re-evaluation of the common standards of treatment.

While targeted cancer therapies are now more tumor-specific and less toxic, and offer new possibilities for tailoring cancer treatment, there are still so many missing pieces: often as not, oncologists are shooting in the dark, trying to tailor the right treatment for their patient with very limited data. With the shadow of Covid, and the multiple risks cancer patients now face, clinicians are increasingly concerned.

"There are very few good biomarkers that enable personalized treatment regimens and therefore, in ... [+] most cases, we have a one size fits all approach."

Today, we use protocols to treat our patients with lung or other kinds of cancers, says Dr. Ofer Sharon, a longtime physician and entrepreneur. There are very few good biomarkers that enable personalized treatment regimens and therefore, in most cases, we have a one size fits all approach. Treatment starts following diagnosis and staging and we start to follow up on patients using clinical capabilities. Then what he describes is rather disturbing. Doctors are left to speculate as to which degree patients are responding to treatment. Usually, response assessment happens after three and six months. During this period, there are a lot of uncertainties, and sometimes there are adverse events and associated costs. If the patient is not responding the way we had hoped, we lose valuable time. There is a consensus among clinicians, he notes, that not all patients are the same and theres a dire need for effective tools to differentiate between patients and personalize treatment according to their needs.

OncoHost, an Israeli precision oncology company is now in the final steps of finalizing a host response profiling platform for predicting patient response to cancer therapeutics.

With over 20 years of experience in clinical and commercial product development for startups in the health tech, biotech, and medical device industries, Dr. Sharon decided to join OncoHost, as its CEO, following a personal tragedy. Seven years ago my father-in-law was diagnosed with advanced-stage melanoma. At the time, I was the medical director for Merck (MSD) and involved in the phase 3 trials of Keytruda, a drug that treats melanoma. Unfortunately, my father-in-law didnt meet the inclusion criteria for the trial and passed away three months before we launched the new drug. The frustration, which arises from the fact that in most cases we just dont know in time which patients will benefit from treatment and which will not, kept me awake for many nights.

When he came across Oncohost, he realized there might be hope for others. I was fascinated by the concept and science. The opportunity to make such a crucial difference in the way we treat cancer was something I just couldnt pass up, and I decided to take on this huge challenge.

The companys technology is based on high-throughput protein analysis, machine-learning algorithms, and bioinformatics tools. Its product, PROphetTM, is currently under study in a multi-center international clinical trial to predict patient response to immune-checkpoint inhibitors for non-small cell lung cancer and melanoma.

"Potential combination strategies and alternative treatments that may mitigate treatment ... [+] resistance." Dr. Ofer Sharon

So far, it has successfully identified a 10-protein signature that distinguishes between responders and non-responders to anti-PD-1 monotherapy or anti-PD-1 and anti-CTLA-4 combination therapy for melanoma. The technology should elucidate protein patterns associated with resistance to immune checkpoint inhibitors and will fulfill the need for differentiating responders from non-responders while monitoring the immune checkpoint inhibitor specific protein expression scores such as tumor proportion score.

The system, now in the clinical trial stage, analyzes the patients response and provides the patient and physician with a response prediction. In cases where no response is predicted, it suggests potential combination strategies and alternative treatments that may mitigate treatment resistance. "We hope this platform will like a CT or MRI add much-needed clinical information to support the complex and in many cases, life-and-death decision-making process".

The technology for assessing response to lung cancer therapy is expected to become available in the U.S. by next year.

Read this article:

By Next Year, Will Doctors Finally Have The Technology To Fully Personalize Treatments For Lung Cancer Patients? - Forbes

BMW launches its world-first eDrive Zones technology in the UK – Automotive World

Posted on August 8, 2020 by Danzig

As cities increasingly discuss the introduction of low emission zones, BMW is making another important contribution to boost the uptake and attractiveness of electromobility among consumers, by launching BMW eDrive Zones in London and Birmingham. With electric ranges of up to 54 miles, BMW plug-in hybrid models are built with cities in mind, as they can complete most commuting trips on pure-electric power. This new technology helps drivers do just that.

BMW eDrive Zones is a new digital service which automates the process of switching to electric-only power when a BMW plug-in hybrid vehicle enters a defined area of these cities. The service, unique in the worldwide automotive industry, also automatically ensures that the electric power is conserved for use during the part of the journey within the low emission zone, if the journey destination is entered into the vehicles navigation system.

This new technology ensures BMW plug-in hybrid models offer consumers the best of both worlds: electric-only driving in the city, where it makes the most difference and a highly efficient internal combustion engine to cover long distances.

This is the flexibility that customers want, as they make the transition to electromobility said Pieter Nota, BMW AG board member for Customer, Brands, Sales commenting on the UK launch of BMW eDrive Zones. A plug-in hybrid vehicle combines the best of two worlds: emission-free city-driving as well as long-distance capabilities. We urge governments to prioritise plug-in hybrid vehicles in order to encourage consumers to live a more sustainable lifestyle. BMW eDrive Zones technology supports customers to drive emission free in London and Birmingham. It improves air quality in cities fast and reduces running costs for drivers. Its win-win for everyone, Nota added.

The BMW eDrive Zones service, available as standard on BMW plug-in hybrid models running the latest BMW Operating System 7.0, uses geo-fencing technology via GPS within the vehicles navigation system. The eDrive Zones in London and Birmingham are highlighted graphically on the vehicles Central Control Display navigation screen, so drivers can see their location.

This feature, which is enabled in customer vehicles as of today, covers the same geographic area as the TFL Congestion Charge/ULEZ zone in London, whilst in Birmingham the service covers the citys planned Clean Air Zone, which is due to be implemented in 2021. BMW plans to introduce this technology in additional cities across the UK and Ireland in the future.

The BMW eDrive Zones service is now available as standard on BMW 330e, BMW 530e, BMW 745e and BMW X5 xDrive45e, with additional compatible models launching in the future. BMW eDrive Zones has also been made available via a free over-the-air software update for compatible BMW plug-in hybrid vehicles, meaning existing customers can also benefit from this technology.

The significant contribution plug-in hybrid vehicles can make to reducing tailpipe emissions in cities was demonstrated in an early trial of this technology, carried out in the Netherlands in 2018. Results of this research project showed 90 per cent of all routes within the trial zone in Rotterdam were driven in electric-only mode.

BMW Group production locations in the UK are also contributing towards the companys global electromobility goals. BMW Groups Hams Hall engine manufacturing plant, near Birmingham, assembles three-cylinder and four-cylinder petrol engines that are at the heart of a number of BMW and MINI plug-in hybrid vehicles. By the end of 2020, it is expected that one in five engines built by the company in Birmingham will be destined for a plug-in hybrid vehicle, rising to around 25 per cent of engines built next year.

At MINI Plant Oxford, the global centre of MINI manufacturing, production of the brands first battery-electric car started earlier this year. Last week, just before the plants annual summer shutdown, Plant Oxford hit a production milestone with 11,000 MINI Electric models built since production begun.

SOURCE: BMW Group

Follow this link:

BMW launches its world-first eDrive Zones technology in the UK - Automotive World

What is China’s New Infrastructure Plan and Will it Benefit Tech Investors? – China Briefing

Posted on August 8, 2020 by Danzig

Building new infrastructure ( or for short) has recently become a top development priority for China and refers to infrastructure that is digital, smart, and innovative.

As part of its post-COVID-19 relief package, China is ramping up plans to construct new digital infrastructure across the country including building 5G networks, artificial intelligence (AI), Internet of Things (IoT), intercity high-speed rail, and setting up research and development institutions.

In doing so, a new wave of government support for private sector participation can be seen through the issuance of special bonds, encouraging public-private partnerships, or extension of credit support.

These plans work in concert with Chinas other industrial policies like Made in China 2025 and China Standards 2035 Plan which together signal Chinas ambitious long-term strategy of becoming the global leader in high-tech and innovative industries of the future.

New opportunities now exist for early investors looking to participate in these fast-growing technology industries and subsectors. In addition, large industry players have the chance to invest in projects that will propel the commercialization of emerging technology.

Foreign investors should continue to follow-up on the latest policy developments in their target area of investment, as more government policies will likely be released shortly to guide the development of each of these new technologies.

In this article, we explain what we know about Chinas new infrastructure plan so far, along with the opportunities for investors to get involved.

At the 2020 National Peoples Congress, the CCP announced that in addition to doubling down on itsMade in China 2025andChina Standards 2035 initiatives, it would spend approximately US$1.4 trillion on a digital infrastructure public spending program.

The new infrastructure includes seven key areas: 5G networks, industrial internet, inter-city transportation and rail system, data centers, AI, ultra-high voltage power transmission, and new-energy vehicle charging stations.

Originally touted as a way for China to achieve domain independence and accelerate its industrial upgradation, the new infrastructure plan has transformed into a long-term national economic strategy.

However, in April 2020, the National Development and Reform Commission released a revised categorization of new infrastructure to include three broad aspects of next-generation technology:

Infrastructure with public benefits, which support science and technology infrastructure, science and education infrastructure, and industrial technology innovation infrastructure.This includes R& D institutions, research infrastructure, and innovation-focused industrial parks.

The foundation of this technological development and refers to technology that increases productivity, speed, accuracy, and breadth of information collected, stored, disseminated, and analyzed.This includes 5G, IoT, industrial internet, AI, cloud computing, blockchain, data centers, and internet communication network infrastructure.

Fusion infrastructure formed through the application of internet, big data, AI, and other technologies to support the transformation and upgradation of traditional infrastructure.This includes constructing inter-city high-speed rail and inner-city rail systems, charging stations for electric vehicles (EVs), and ultra-high voltage (UHV) power transmission.

Broadly speaking, these three categories have three main functions

According to estimates from analysts at the CCID Think Tank Electronic Information Institute, a government-affiliated think tank as well as Haitong Securities, a major Chinese securities firm, the investment associated with new infrastructure projects is expected to total around RMB 10 trillion(US$ 1.43 trillion) toRMB 17.5 trillion (US$2.51 trillion) for the next five-year period until 2025.

Since the NDRC clarified the scope of what is new infrastructure, 25 provinces have launched their own local plans.

Among them is the Shanghai plan, which set the total investment target for the next three years at RMB 270 billion (US$38.7 billion), while Guangzhou signed 16 digital new infrastructure projects with a total investment of RMB 56.6 billion (US$8.09 billion). Zhejiang province, home to tech giant Alibaba, also committed to a new batch of projects 61 percent of which are in the high-tech field, a 20 percent increase from the previous year.

Xu Xianping, former deputy director of the NDRC estimates that: the scale of upstream and downstream businesses in the industrial chain will see RMB 2.8 trillion (US$400 billion) in investment, with an average annual growth rate of 22.6 percent.

The same momentum can be seen across different types of technology, where for example, China has announced that by 2025, it will invest RMB 500 billion (US$72 billion) in UHV, RMB 100 billion in AI chips, and RMB 650 billion (US$93.4 billion) in the industrial internet. In terms of 5G networks, China has committed to constructing five million 5G base stations by the end of 2025 a 25-fold increase in less than five years.

Compared to the state-led investment push in traditional infrastructure in the wake of the 2008 global financial crisis, the biggest distinction in the 2020 stimulus package is that this time round the government is much more reliant on market forces and private investment.

Thus, there are many more opportunities for business stakeholders to participate in this next phase of Chinas development.

Still, each sector will see varying degrees of government investment. Consequently, private technology firms will need to assess whether they willing to align their participation with government directives to form partnerships with state-owned-enterprises.

For example, research and satellite communications will have a high government investment ratio, whereas application developments, virtual reality, 3D printing, and smart robot production will typically be comprised of private investments and have relatively low industry barriers for foreign investment.

Ultimately, openness to foreign investment will depend on whether the sector is mentioned in the Special Administrative Measures for Access to Foreign Investment Negative List (2020 Edition) or the Catalogue of Encouraged Industries for Foreign Investment Encouraged List (2019 Edition).

Based on these lists, foreign investment in internet data centers and 5G networks face the most stringent restrictions, while investment in industrial internet, NEVs, and AI are generally perceived to be the most foreign-investment friendly with many upstream and downstream subsectors featured on the encouraged list.

Recently, China also released the exposure draft of its Catalogue of Encouraged Industries for Foreign Investment (2020 Edition), which further encourages foreign-invested enterprises to participate in the high-tech development of its manufacturing industry.

The 2020 draft catalogue proposes to expand the list to include a further 56 items, adding manufacturing of LiDAR (light detection and ranging) and millimeter-wave (MMW) radars related to autonomous driving technology as well as manufacturing of charging piles. In the fields of computer, communication, and electronics manufacturing, the proposed list added manufacturing of smart wearable devices, intelligent unmanned aerial vehicles (UAVs), customer service robots, and smart home systems and equipment.

Though this draft catalogue is still currently undergoing its final round of public consultation, if implemented, it will further open up a range of high-tech sectors to foreign investors.

Foreign-invested enterprises who invest in encouraged industries will be subject to tariff exemptions, preferential land prices, looser regulation of land uses, and lowered corporate income tax. However, those industries that appear on the negative list will either be restricted or prohibited from foreign investment entry.

We will examine seven key sectors of Chinas new infrastructure, and their openness to foreign investment below.

Similar to the trend in other countries, Chinas small and medium-sized enterprises (SMEs) have been a critical driver of innovation, and currently account for approximately 66 percent of the patents issued.

Though direct investment in infrastructure may not be a viable option for SMEs, there are many opportunities either upstream or downstream of the supply chain where they can participate.

There are two sides to the potential opportunities available for SMEs supply and demand. Businesses can either choose to participate in the construction and manufacturing of these new technologies or participate in the commercial application of these technologies across various sectors.

On the supply side, there are other opportunities that exist on the periphery of this large-scale infrastructure build.

For small-to-medium enterprises, many opportunities exist in the upstream (manufacturing of equipment) and downstream (program development) of the industry chain and are encouraged by the government.

Take 5G for example though investment in the network itself is, in practice, an area that is restricted to a few large Chinese players, there are opportunities that exist within the supply chain.

This is particularly true of the automobile industry; for example, 5G network giant Huawei recently announced that it willpartnerwith 18 carmakers, including FAW group, BYD, and T3 Mobility, to build a 5G-enabled automobile ecosystem in the automobile industry moving to accelerate the uptake of 5G technology in smart cars and achieving a significant transformation of its industrial capacity.

Investments into the upstream segment of supply chain attached to 5G networks continue to be in encouraged category for foreign investors, including:

On the demand side, there are a whole array of new use scenarios that will come with the advent of each new type of next-generation technology.

Using the same 5G example, which offers a combination of faster speed, higher capacity, and lower latency this will enable the digitalization of traditional business models. As 5G technology matures, there will be greater opportunities for it to be applied across industries.

Traditional industries, such as medical care, education, retail, manufacturing, services, and logistics will all inevitably have to shift towards digital business models that will adapt to the radical digital transformation or application of new technologies.

For example, CloudMinds Technology, a SoftBank-backed startup in Beijing,donatedrobots with 5G-enabled cloud-based systems to Wuhans hospitals. The robots worked 24/7 hours and undertook jobs like remote nursing, body temperature taking, heart rates and blood oxygen levels measurement, medication delivery, disinfection, and cleaning.

Though there are many opportunities in Chinas tech industry for investors, as the global technology industry becomes increasingly politicized, the challenges may amplify.

As discussed in the Hinrich Foundations report titled Strategic US-China Decoupling in the Tech Sector, the global tech industry continues to see an a heightened sense of techno-nationalism, displayed through a set of mercantilist-like behaviors that link tech innovation and enterprise directly to the national security, economic prosperity and social stability of a nation.

This is especially so as China-US geopolitical competition reaches a tipping point, and mutual tariff hikes, US restriction on exports of high-tech goods and services to China, and targeted restrictions of large tech companies with strong national ties (Huawei and Tiktok) result in an inevitable reshuffling of technological supply chains between the two countries.

Going forward, a much clearer distinction will now be made between foreign and domestic players, a point strongly emphasized by the recent Hinrich Foundation report.

Subsidies, government-backed credit programs for customers, and the Digital Belt and Road Initiative [all] contributed to the meteoric rise of Huawei, and Chinese tech companies in general, the report explains. The US, EU and other state-actors will focus increasingly on countering Beijings economic nationalism with techno-nationalism initiatives of their own.

Countries around the world will continue to be locked in a race to become the first to successfully develop, commercialize, and thus set the standards for the many types of new generation technology that are set to emerge.

Indeed, this is already starting to precipitate with the emergence of the China Standards 2035 Plan, which is an initial blueprint of the standardized processes and specifications to ensure products in the tech industries worldwide are built to work together seamlessly.

Though a growing sense of techno-nationalism will inevitably follow, a complete technology decoupling is unlikely to prevail as technology supply chains still require the participation of many foreign players.

In China, one clear example of this is the semi-conductor industry where China still overwhelmingly relies on foreign companies for its supplies only 16 percent of its semiconductors are produced in the country as of 2019.

Although China has spent billions of dollars in earlier decades to create a domestic semiconductor industry a critical component of the technology supply chain this has come with little success. The chief difficulty for Chinese firms is not access to equipment but their lack of experience and know-how.

Therefore, foreign companies still have a large role to play where current domestic capabilities in Chinas tech industry fall short, particularly, where industries like the semiconductor industry have recently become beneficiaries of a slew of new government preferential policies.

Managers and strategic investors should seek out experts on the ground to craft an appropriate market-entry strategy that accounts for the newly arisen challenges in an increasingly competitive but opportunity-filled landscape.

About Us

China Briefing is written and produced by Dezan Shira & Associates. The practice assists foreign investors into China and has done so since 1992 through offices in Beijing, Tianjin, Dalian, Qingdao, Shanghai, Hangzhou, Ningbo, Suzhou, Guangzhou, Dongguan, Zhongshan, Shenzhen, and Hong Kong.

Please contact the firm for assistance in China at china@dezshira.com. We also maintain offices assisting foreign investors in Vietnam, Indonesia, Singapore, The Philippines, Malaysia,Thailand, United States, and Italy,in addition to our practices in Indiaand Russia and our trade research facilities along the Belt & Road Initiative.

Go here to see the original:

What is China's New Infrastructure Plan and Will it Benefit Tech Investors? - China Briefing

Another Life: Our second ash comes into conflict with technology – The Irish Times

Posted on August 8, 2020 by Danzig

I could have looked up when kneeling to plant the little ash tree some 30-odd years ago. Then I might have considered the powerline high above me, strung from the transformer beyond the hedge to the pole beside the house.

But perhaps I just couldnt imagine the ambition locked up in the sapling I was firming in.

This summer, as the trees topmost twigs reached up to embrace the wire, I began to dread the approach of early autumn storms. It was time to consult the ESB.

Theyre jolly decent in these matters. If the offending tree is beyond the immediate domestic pole, they will, in good time, despatch a remedial team with a baby chainsaw on a very long pole.

This was, sadly, our second ash to come into conflict with technology. A tree planted closer to the house grew into a strong-muscled, shapely candelabra, beautiful in every season. But it came to obstruct the wireless beams by which we shared our broadband with neighbours. Its pollarding prompted final felling, to our mutual regret.

Meanwhile, the wayside ashes of the west stand as defiantly healthy emblems of their kind. Further east, and across the midlands, hedgerow ashes and forest plantations have been scarred by the single most devastating forest pathogen ever to hit the postglacial woodlands of Ireland. That was Teagascs blunt summation of Chalara ash dieback, wrought by the Asian fungus Hymenoscyphus fraxineus.

Since its first discovery in Co Leitrim in 2012, its airborne spores have had worst impact on young ash plantations, their leaves wilting and blackening into death. It is now established in all counties in Ireland, but as yet spares large reaches of the western seaboard, saved by Atlantic winds.

In 2013, the Department of Agriculture, Food and the Marine devised a reconstitution scheme to help in clearing affected plantations and planting them with alternative species. By 2018, this had cost some 5.8 million, for more than 1,000 hectares, but it stopped when scientists advised that eradication of ash dieback was no longer feasible.

After widespread damage throughout Europe, the research priority is finding the small minority of ash trees that are tolerant of the disease, passing on their tolerance genetically.

Actual resistance to the fungus has not been found in any common ash population. And even naturally tolerant trees, left to themselves, could take many decades or even centuries to evolve any widespread, rural equilibrium.

Thus, say geneticists working with Irelands Council for Forest Research and Development (Coford), the focus is on breeding from tolerant trees and spreading their progeny to forests and hedgerows over a much shorter time.

Even to identify tolerant trees needs an environment where the pressure of disease is high and their stubborn health quite evident. This is still unusual in Ireland, so most of the breeding programmes are in Europe.

However, Teagascs forestry researchers have had access to ash trees of widely varied Irish provenance already growing in six countries and planted for an earlier, unrelated trial. They include 1,000 trees in Lithuania and 14,000 in the UK. Using such material from Belgium ,they have identified chemicals in the ash that distinguish tolerant trees from those sensitive to dieback.

Two bark chemicals most strongly associated with tolerance belong to the family of coumarins, their sweet scent familiar from freshly mown hay. Such molecular signals are now helping to seek out tolerant trees in Irish stands.

Dr Gerry Douglas, just retired from Teagascs breeding ash research, puts such trees at 1 to 2 per cent. The best news, he says, is that this natural resistance in ash is heritable, and also highly stable in trees that are propagated vegetatively.

This is different, as he points out, from the restorative breeding of disease-resistant elms, which involves introduction of new genes from Asian elm species.

The ash-breeding programme will need large nurseries to propagate trees by grafting and for production of cuttings for rooting. A second stage begins with producing small amounts of seed from grafted trees grown in high polytunnels.

This needs controlled pollination of mother tree flowers from tolerant father trees. Later, more seed can come from orchards of tolerant trees grown from grafts and rooted cuttings.

All this will take years, as Coford sets it out, perhaps as long as 20. But Gerry Douglas is confident that the programme will produce resistant ash seed for sprinkling along the hedgerows.

Go here to read the rest:

Another Life: Our second ash comes into conflict with technology - The Irish Times

Not just a fad, cloud provides the foundation for future technologies – Federal News Network

Posted on August 8, 2020 by Danzig

This content is provided byRed Hat.

Every year or so, theres a big pushback that labels the cloud as just a fad. One popular argument posits that it doesnt even exist, since its really just someone elses computer. While your average hands-on-keyboards types tend to be more up-to-date on such technologies, its surprisingly common for executives to be less in touch, deciding to skip cloud technologies in favor of seeing what comes next. Within the historical context of IT advances, it becomes clear that this is a mistake; cloud is here to stay, and the next generation of technologies is already being built on its foundations.

There have been a lot of very specific steps over the course of history that have taken us from the mainframe days to where we are now. These steps have shaped our direction into the future, said Damien Eversmann, senior solutions architect for Red Hat Public Sector.

When enterprise IT began with the mainframe, the systems administrators did everything, and the code base was monolithic. But as technology sped up, it diversified, which led to servers. Data sat on one server, business logic on another, and sometimes there would even be a front end presentation layer in the form of a client application, or eventually web browser login. And each of those layers were overseen by a different specialist; as the technology layers diversified, so did the technologists.

Then the number of applications being created continued to grow, Eversmann said. And instead of having people specialize in one layer, people started to break things out into what we now call services oriented architectures. This is the precursor to microservices, one of the main things that were looking at with the cloud now.

Once things started getting broken down into individual services, people realized that those services could be reused. For example, everyone needs a login function. So why not write it once, and share it across all applications?

Now we can scale a much smaller, more granular piece to keep our entire application performing at its best. And this is where making that transition to the cloud was important, Eversmann said. Because the way things were with services oriented architecture, we had reached the limit of what could happen in your data center.

But some people like to point to the pendulum effect around where compute resides to justify waiting until the cloud fad passes. Compute moves from the core, to the edge, back to the core again. From mainframes to workstations to data centers to web browsers.

If the current utilization of cloud is just the pendulum swinging back to the core, albeit one that no longer exists in data centers, why not wait until the pendulum swings back, and skip cloud altogether?

Because it turns out the pendulum metaphor is a little simplistic. Eversmann has a better one.

You know in movies, the ninja that jumps up the alley by jumping back and forth between the buildings? Your pendulum is swinging back and forth but at the same time you keep popping higher and higher, Eversmann said. And thats whats happening here:as we go back and forth between this data at the core, data at the edge, were also leapfrogging the technology of the last time.

In fact, that hypothetical pendulum (or wall-jumping ninja, if you will) is already moving back in the other direction. Technological advancements like the Internet of Things and 5G are enabling so much data to be gathered at the edge that its stressing network bandwidth to send it back to a centralized location for processing. Accordingly, many federal agencies are already looking at and planning for the ability to push compute back out to the edge, so the data gets analyzed in the field where its collected, and the only thing that gets pushed back is the analysis itself.

And youd think that that was a contrary argument to the cloud, right? But its not because if you look at how you define the edge, its actually the cloud, Eversmann said. We now suddenly have the cloud on both sides of this pendulum swing. If we swung into far off servers that are really powerful, thats the cloud. As we need to bring computing closer to the masses, were not bringing it to their desktop anymore. Were bringing it to an edge computing node on the cloud.

Thats why you cant just skip the cloud and see what comes next. Cloud isnt the technology; its the platform.

If you look at some of the functionality and the compute capabilities that live in these hyper-scalers, like AWS or Azure, its stuff that you cant really get in your data center without becoming a hyper-scaler yourself, Eversmann said. There are things that were doing now, with function-based computing and serverless computing that cant be matched without going to the cloud.

Not just a fad, cloud provides the foundation for future technologies - Federal News Network

Bodle Technologies announces world’s first TFT driven Solid State Reflective Display fabricated on a GEN2.5 line – Digital Signage Connection

Posted on August 8, 2020 by Danzig

Bodles Taiwan Team Albert Tsai, TS Jen and Luc Lai with the SRD prototype panel at Taiwans ITRI

Oxford UK, 7 August 2020.Bodle Technologies Ltd has developed the worlds first TFT driven Solid State Reflective Display (SRD) fabricated on a GEN2.5 line at Taiwans Industrial Technology Research Institute (ITRI).

Led by Bodles VP for Manufacturing, TS Jen, the team in Taiwan transferred the designs and research activities directly from the Oxford based team to produce the test displays.

TS Jen comments: This is an important milestone for Bodle, giving us the confidence that our technology is manufacturable using standard processes. We are delighted to be doing this in an ecosystem where many new display technologies have been launched.

The SRD is an ultra-low power, colour reflective display, based on phase-change materials, which work over a wide range of temperatures. They have applications in areas such as mobile second screens, electronic shelf edge displays as well as personalized jewellery and watches.

New VP of Materials and Engineering, Andrew Pauza adds: To see this technology being scaled from a few pixels on R&D samples made on a lab coater to work on displays with nearly a quarter of a million pixels, made on a production coater is fantastic. Many of the materials and production processes are based on those used for rewritable optical disc, an area where I have worked for many years. We have been able to apply these processes to accelerate this move to a more manufacturable process for the SRD.

This step forward provides further impetus to the companys expansion and scale up plans within Taiwan as it looks to commercialise its technology within the coming years.

###

Picture caption:Bodles Taiwan Team Albert Tsai, TS Jen and Luc Lai with the SRD prototype panel at Taiwans ITRI

About Bodle Technologies Ltd

Bodle Technologies is developing SRD, the worlds first solid-state reflective display technology, based on phase-change materials. Providing vivid colour and video-capability, with zero energy use for static image storage, the technology is ideally suited to address the issues of poor outdoor readability and high power consumption associated with transmissive and emissive displays.

Invented at the University of Oxford, the science behind SRD was first published in Nature during 2014.

Bodle was founded the following year and has a growing IP portfolio covering this new display technology. Bodles investors are led by Oxford Sciences Innovation (OSI)

http://www.bodletechnologies.com

Bodle Technologies announces world's first TFT driven Solid State Reflective Display fabricated on a GEN2.5 line - Digital Signage Connection

Color Star Technology Announces Machine Gun Kelly will join its "Fearless, Color World" Online Concert – PRNewswire

Posted on August 8, 2020 by Danzig

NEW YORK, Aug. 7, 2020 /PRNewswire/ -- Color Star Technology Co., Ltd. (Nasdaq CM: HHT) (the "Company"," we", or "HHT") is pleased to announce that American rapper, singer, songwriter and actor Machine Gun Kelly will join the Color World app owned by the company for its online concert "Fearless, Color World" on September 9th. As one of the leading talents in global pop music, alternative, and hip hop, he is sure to bring fans of all background a moment to be remembered.

"Fearless, Color World" online concert is a new type of concert launched by Color Star Technology which provides innovative art Training Service. The concert has invited many world-class artists to perform, hoping to make the audience feel the peace of the world, and the eternal love.

Machine Gun Kelly is an American well-known rapper, he embarked on a musical career as a teenager, releasing a mixtape in 2006. After he joined Interscope Records which is owned by Universal Music Group, his first major label debut album "Lace Up" reached number 4 on the Billboard 200 chart and sold more than 178,000 copies. In addition, his singles "Till I die" and "A little More" for his second studio album debuted at number four in the US, and "Bad Things" in his third studio album "Bloom" peaked number 4 on the Billboard Hot 100.In addition to his music career, he has acted in a number of Americanfilms.

Biao (Luke) Lu, CEO says "We are thrilled to partner with Machine Gun Kelly in the planned concert, a live event featuring colorful music, colorful life, and a colorful world. With warmth and hope, we celebrate our own lives and the hopes of the world. The performance brought by Machine Gun Kelly will channel through the Color World platform to reach hundreds of millions of potential audiences around the world. With dazzling stage design and top audio equipment, we believe that this online concert will definitely bring our platform users a brand-new online concert experience."

About Color Star Technology Co., Ltd.

Color Star Technology Co, Ltd. (Nasdaq: HHT) offers online and offline innovative education services for music and entertainment industries globally. Its business operations are conducted through its wholly-owned subsidiaries Color China Entertainment Ltd. and CACM Group NY, Inc. The Company's online education is provided through its Color World music and entertainment education platform. The Company also offers after-school entertainment tutoring inNew Yorkvia its joint venture entity Baytao LLC.

Machine Gun Kelly Biography

Colson Baker, also known as "Machine Gun Kelly," is a multi-hyphenate talent with an impressive career that started in Cleveland and has made him a globally known star in both music and film.

As Machine Gun Kelly, he burst onto the music scene with therelease of his first albumLace Upvia EST 19XX/Bad Boy/Interscope Records. The album debuted at number two on Billboard's R&B/Hip-Hop Albums chart. He won "US Artist About to Go Global" at the 2012 MTV EMA's and MTV's 2012 "Breaking Woodie" Award. The following year he was awarded "Woodie of the Year" beating out A$AP Rocky, Fun, Grimes and Kendrick Lamar. His 2015 sophomore album,General Admissionclinched a #1 spot on Billboard's R&B/Hip-Hop Album charts. He's performed on THE VOICE, THE TONIGHT SHOW WITH JIMMY FALLON, THE LATE LATE SHOW WITH JAMES CORDEN, ELLEN, BET's 106 AND PARK, THE NICKELODEON KIDS CHOICE AWARDS and several other programs and award shows. His songs have appeared in soundtracks for the feature films BRIGHT and WHY HIM?.

Spotify recently released that his songs were streamed 571,200,000 times in 79 countries in 2019. His most recent albumHotel Diablowas released July 5, 2019 and was supported by three singles: "Hollywood Whore", "El Diablo", and "I Think I'm Okay" (featuring Travis Barker and Yungblud). "I Think I'm Okay" became a certified Gold Single in December of 2019. In 2017, his albumbloomwent gold. The album track "Bad Things" featuring Camila Cabello, sold 8+ million worldwide, was nominated for a 2017Billboard Music Award and owned the Billboard 100 list for 16+ weeks in 2017. The song has had more than 245m+ streams with a radio audience of 145m, becoming RIAA certified 3x platinum (domestic) and 8x worldwide. "Machine Gun Kelly" was one of the top ten most searched artists of 2018 according to Google. In April 2020, he released "Bloody Valentine," the first single off his forthcomingTickets to My Downfall album, executive produced by Travis Barker. The two appeared on THE LATE LATE SHOW WITH JAMES CORDEN to perform the song, and the official video starring Megan Fox garnered over 4,000,000 views in under 24 hours.

On the acting side, he received critical acclaim as thelead role as Tommy Lee in the Netflix'sTHE DIRT, a biopic based on the rise of the band Motley Crue directed by Jeff Tremaine. He also starred opposite Sandra Bullock, John Malkovich and Trevante Rhodes in Netflix's thriller film BIRD BOX. In its first week of streaming, 45,037,125 Netflix accounts watched the film, making it Netflix's most streamed film at the time. He appeared in BIG TIME ADOLESCENCE from writer/director Jason Orley, also starring Pete Davidson, Griffin Gluck and Jon Cryer, which premiered in competition at the 2019 Sundance Film Festival and wasreleasedby NEONon Hulu inMarch 2020. He will next be seen in Netflix's PROJECT POWER from Henry Joost and Ariel Shulman also starring Jamie Foxx and Joseph Gordon-Levitt which will premiere globally inAugust 14, 2020.

Previously, Baker starred on Cameron Crowe's Showtime series ROADIES, playing Wes, a recently fired Pearl Jam roadie who joins his twin sister Kelly Ann (Imogen Poots) on tour for the fictitious Staton-House Band. The series also starred Luke Wilson and Carla Gugino and was executive produced by Cameron Crowe, JJ Abrams, Winnie Holzman and Bryan Burk.

He appeared alongside Dave Franco and Emma Roberts in the Henry Joost/Ariel Shulman Lionsgate film NERVE, opposite Gugu Mbatha-Raw in Gina Prince-Bythewood's BEYOND THE LIGHTS, and in James Merendino's PUNKS DEAD: SLC PUNK 2. Additional films include the Rupert Wyatt directed film CAPTIVE STATE with Ashton Sanders, Vera Farmiga and John Goodman.

At 6'4', the musician/actor has walked in New York Fashion Week, and his distinct look and love for fashion landed him a campaign as the face of John Varvatos for Fall/Winter 2017-2018. Combining his musical talents with the campaign, he played the opening of Varvatos' first ever store in Dubai in November 2018. He also collaborated with Reebok on their Club C sneaker campaign.

When not touring or filming, he resides in Los Angeles.

Forward-Looking Statements

Certain statements made herein are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include the business plans, objectives, expectations and intentions of the parties following the completion of the acquisition, and HHT's estimated and future results of operations, business strategies, competitive position, industry environment and potential growth opportunities. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, our actual results may differ materially from our expectations or projections. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: there is uncertainty due to the COVID-19 pandemic and the impact it will have on HHT's operations, the demand for the HHT's products and services, global supply chains and economic activity in general. These and other risks and uncertainties are detailed in the other public filings with the Securities and Exchange Commission (the "SEC") by HHT. Additional information concerning these and other factors that may impact our expectations and projections will be found in our periodic filings with the SEC, including our Annual Report on Form 20-F for the fiscal year ended June 30, 2019. HHT's SEC filings are available publicly on the SEC's website at http://www.sec.gov. HHT disclaims any obligation to update the forward-looking statements, whether as a result of new information, future events or otherwise.

Color Star Technology Co., Ltd. Contact: Investor Relations FinancialBuzzIR [emailprotected]Tele: +1-877-601-1879

SOURCE Color Star Technology Co., Ltd.

See the rest here:

Color Star Technology Announces Machine Gun Kelly will join its "Fearless, Color World" Online Concert - PRNewswire

5G and Cloud Computing Technologies Market Report, History and Forecast 2020-2026, Breakdown Data by Manufacturers, Key Regions, Types and Application…

Posted on August 8, 2020 by Danzig

The report Global 5G and Cloud Computing Technologies Market offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape.

The main objective of this market research is to help the readers understand the structure of 5G and Cloud Computing Technologies market, market definition, overview, industry opportunities and trends, investment strategy with forceful and reliable data.

To Get The Sample Copy @ https://www.reportsandmarkets.com/sample-request/global-5g-and-cloud-computing-technologies-market-2019-2025?utm_source=thediamondreport&utm_medium=14

Key Players: ADLINK Technology Inc.,Advanced Micro Devices,Advantech,,Akamai Technologies,Allot Communications,Amazon Web Services,Ampla Soluciones SL,AT&T Inc.,Aware360 Ltd.,Broadcom Corporation,Brocade Communications Systems,C3IoT,,Carriots,Cavium Networks,Ceragon Networks,China Mobile,Cisco Systems Inc.

The final report will add the analysis of the Impact of Covid-19 in this report 5G and Cloud Computing Technologies industry.

5G and Cloud Computing Technologies Market continues to evolve and expand in terms of the number of companies, products, and applications that illustrates the growth perspectives. The report also covers the list of Product range and Applications with SWOT analysis, CAGR value, further adding the essential business analytics. 5G and Cloud Computing Technologies Market research analysis identifies the latest trends and primary factors responsible for market growth enabling the Organizations to flourish with much exposure to the markets.

Market Segment by Regions, regional analysis covers

Make an Enquiry @https://www.reportsandmarkets.com/enquiry/global-5g-and-cloud-computing-technologies-market-2019-2025?utm_source=thediamondreport&utm_medium=14

Research objectives:

To study and analyze the global 5G and Cloud Computing Technologies market size by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2026.

To understand the structure of 5G and Cloud Computing Technologies market by identifying its various sub segments.

Focuses on the key global 5G and Cloud Computing Technologies players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the 5G and Cloud Computing Technologies with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the size of 5G and Cloud Computing Technologies submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.

Table of Contents: 5G and Cloud Computing Technologies Market

Key questions answered in this report

Browse for Full Report at @: https://www.reportsandmarkets.com/checkout?currency=one_user-USD&report_id=3714989&utm_source=thediamondreport&utm_medium=14

About Us:

Reports and Markets is not just another company in this domain but is a part of a veteran group called Algoro Research Consultants Pvt. Ltd. It offers premium progressive statistical surveying, market research reports, analysis & forecast data for a wide range of sectors both for the government and private agencies all across the world. The database of the company is updated on a daily basis. Our database contains a variety of industry verticals that include: Food Beverage, Automotive, Chemicals and Energy, IT & Telecom, Consumer, Healthcare, and many more. Each and every report goes through the appropriate research methodology, Checked from the professionals and analysts.

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Go here to see the original:

5G and Cloud Computing Technologies Market Report, History and Forecast 2020-2026, Breakdown Data by Manufacturers, Key Regions, Types and Application...

World TMS (Transcranial Magnetic Stimulation) Coil Market Industry: A Latest Research Report to Share Market Insights and Dynamics – Bulletin Line

Posted on August 8, 2020 by Danzig

The recent research report titled World TMS (Transcranial Magnetic Stimulation) Coil Market Research Report 2025 (Covering USA, Europe, China, Japan, India and etc) has been added in the kandjmarketresearch.com database. The Global TMS (Transcranial Magnetic Stimulation) Coil Market Perspective, Comprehensive Analysis along with Major Segments and Forecast, 2020-2025.

TMS (Transcranial Magnetic Stimulation) Coil Market Overview

The global TMS (Transcranial Magnetic Stimulation) Coil market has been studied by a set of researchers for a defined forecast period of 2020 to 2025. This study has provided insights to the stakeholders in the market landscape. It includes an in-depth analysis of various aspects of the market. These aspects include an overview section, with market segmentation, regional analysis, and competitive outlook of the global TMS (Transcranial Magnetic Stimulation) Coil industry for the forecast period. All these sections of the report have been analyzed in detail to arrive at accurate and credible conclusion of the future trajectory. This also includes an overview section that mentions the definition, classification, and primary applications of the product/service to provide larger context to the audience to this report.

TMS (Transcranial Magnetic Stimulation) Coil Market Dynamics

The report on the global TMS (Transcranial Magnetic Stimulation) Coil market includes a section that discusses various market dynamics that provide higher insight in the relationship and the impact of change these dynamics hold on the market functioning. These dynamics include the factors that are providing impetus to the market over the forthcoming years for growth and expansion. Alternatively, it also includes factors that are poised to challenge the market growth over the forecast period. These factors are expected to reveal certain hidden trends that aid in the better understanding of the market over the forecast period. Continue reading this report.

The Final Report Will Include the Impact of COVID -19 Analysis about the TMS (Transcranial Magnetic Stimulation) Coil Industry.

Get a free sample copy of this research report @ https://www.kandjmarketresearch.com/sample-request/409826

COVID-19 can affect the global market in 3 ways: by directly affecting the production and demand, by creating supply chain and market disturbance, and by its financial impact on enterprises and financial markets.

Key Players

The global TMS (Transcranial Magnetic Stimulation) Coil market report has provided a profiling of significant players that are impacting the trajectory of the market with their strategies for expansion and retaining of market share.

Key Segments Studied in the Global TMS (Transcranial Magnetic Stimulation) Coil Market:

Global TMS (Transcranial Magnetic Stimulation) Coil Market: Product Segment Analysis:

Global TMS (Transcranial Magnetic Stimulation) Coil Market: Application Segment Analysis:-

The Players mentioned in our report:-

Do You Have Any Query or Specific Requirement? Ask to Our Trade Expert @https://www.kandjmarketresearch.com/enquiry/409826

Global TMS (Transcranial Magnetic Stimulation) Coil Market: Regional Segment Analysis:-

Market Segmentation

The global TMS (Transcranial Magnetic Stimulation) Coil market has been studied for a detailed segmentation that is based on different aspects to provide insight into the functioning of the segmental market. This segmentation has enabled the researchers to study the relationship and impact of the growth chart witnessed by these singular segments on the comprehensive market growth rate. It has also enabled various stakeholders in the global TMS (Transcranial Magnetic Stimulation) Coil market to gain insights and make accurate relevant decisions. A regional analysis of the market has been conducted that is studied for the segments of USA, Europe, Japan, China, India, South East Asia.

Research Methodology

The global TMS (Transcranial Magnetic Stimulation) Coil market has been analyzed using Porters Five Force Model to gain precise insight in the true potential of the market growth. Further, a SWOT analysis of the market has aided in the revealing of different opportunities for expansion that are inculcated in the market environment.

Read More Detailed Information regarding TMS (Transcranial Magnetic Stimulation) Coil Industry with Covid-19 Updates @ https://www.kandjmarketresearch.com/reports/409826-world-tms-transcranial-magnetic-stimulation-coil-market-research-report-2025-covering-usa-europe-china-japan-india-and-etc

If you have any special requirements for the report, please let us know and we will offer you a customized report on separate regional or country-level reports.

About Us:

Kandjmarketresearch.com is part of the KnowledgeNJournals Research Firm which provides premium progressive market research reports, statistical surveying, analysis & forecast data for industries and governments from hundreds of publishers around the world. We have almost all top publishers reports in our collection to provide you with instant online access to the worlds most complete and fresh database on a Daily Basis. We are at KandJ Market Research are inspired to help our clients grow by providing appropriate business insight with our huge market intelligence source.

KandJ Market Research

(Part of KnowledgeNJournals Research)

(USA): +1 661 636 6162 | (IND): +91 932 580 2062

E-mail: [emailprotected]

Website: https://www.kandjmarketresearch.com

Read the original:

World TMS (Transcranial Magnetic Stimulation) Coil Market Industry: A Latest Research Report to Share Market Insights and Dynamics - Bulletin Line

TMS Webinar puts the spotlight on Offshore Oil and Gas – Latest Maritime & Shipping News Online – The Maritime Standard

Posted on August 8, 2020 by Danzig

CEO,Arya Offshore

Cdr. Sunil Dhulekar is the CEO of Arya Offshore which is a group company of J M Baxi Group. Headquartered in Mumbai the company plays host to practically every major player in the upstream sector in India. As a result of its vast experience , Arya Offshore Services brings to the table an unique array of dos and donts to all relevant entrants who need to navigate through the labyrinth of permissions, approvals and statutory compliances relating to operations in port, shipping, logistics and customs.

Arya Offshore Services today is the one of the largest service provider of its kind in India with over 300 trained personnel and with over 1500 contract personnel providing round the clock customized yet comprehensive services to the upstream oil and gas sector.

Cdr Sunil Dhulekar is an alumni of National Defence Academy. Commissioned in 1977 as an Executive Officer in the Indian Navy, his specialisation is Communications. He served on various class of ships ranging from Missile Corvettes upto the aircraft carrier INS Viraat. He retired from Indian Navy in 1999.

Joined Arya Offshore in 1999. Initially, he served in the Operations department of Arya Offshore handling major construction projects executed by clients like Hyundai Heavy Industries, J Ray McDermott, NPCC (Abu Dhabi), L & T (India) etc.

In addition to measuring up to the demanding marine, agency and support service requirements of the industry, Arya Offshore Services has operated multiple user shore cum supply bases in the west coast ports of Mumbai & Bhavnagar and in the east coast ports of Krishnapatnam, Paradip & Visakhapatnam and was instrumental in managing the Marine Shore Bases for British Gas in Mumbai, OAO Gazprom & Allseas Marine Contractors at Visakhapatnam on the East Coast of India. He was the Key Account Manager for a number of seismic companies like Western Geco (Schlumberger group), CGG Veritas, PGS etc. and drilling companies like Deep Water Drilling, ENSCO, Reliance Industries, etc.

He moved up the ladder and took over as Head Business Development in 2006 and subsequently stepped in as CEO of Arya Offshore in 2012.

As CEO of Arya Offshore Services, he has been closely associated in steering the company from a shipping agency to a full-fledged logistics solution provider with a customized range of service-offerings to the offshore and onshore Oil & Gas sector in India.

See the original post here:

TMS Webinar puts the spotlight on Offshore Oil and Gas - Latest Maritime & Shipping News Online - The Maritime Standard

Edited Transcript of GTMS.TO earnings conference call or presentation 5-Aug-20 2:00pm GMT – Yahoo Finance

Posted on August 8, 2020 by Danzig

Aug 6, 2020 (Thomson StreetEvents) -- Edited Transcript of Greenbrook TMS Inc earnings conference call or presentation Wednesday, August 5, 2020 at 2:00:00pm GMT

Greenbrook TMS Inc. - President, CEO & Director

Greenbrook TMS Inc. - CFO, Treasurer & Corporate Secretary

* David C. Martin

Clarus Securities Inc., Research Division - VP & Research Analyst of Growth and Innovation

Welcome to the Greenbrook TMS Inc. Second Quarter 2020 Results Conference Call and Webcast. (Operator Instructions) I would like to remind you that this conference call is being recorded today and is also being webcast on the company's website at http://www.greenbrooktms.com under the Investors section, Events. (Operator Instructions) Analysts and investors are reminded that any additional questions can be directed to the company at investorrelations@greenbrooktms.com.

This call contains forward-looking statements, which reflect the current expectations or beliefs of the company based on currently available information. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations are disclosed under the heading Risk Factors in the company's annual information form dated March 10, 2020, and in the company's MD&A for the period ended June 30, 2020, which are available on SEDAR and on the company's website. Any forward-looking statements speaks only as of the date on which it is made, and the company disclaims any intent or obligation to update any forward-looking statement unless required by law.

I would now like to turn the meeting over to Mr. Bill Leonard, President and Chief Executive Officer of Greenbrook TMS; and Erns Loubser, Chief Financial Officer. Go ahead, please, Mr. Leonard.

Bill Leonard, Greenbrook TMS Inc. - President, CEO & Director [2]

Thank you, Lindsey, and thank you to everyone for joining our conference call and webcast today. We are very excited about our Q2 2020 results, which demonstrates our ability to navigate and grow during the challenging operating environment imposed by the COVID-19 pandemic. Overall, we were able to continue to grow our business even more than we expected, exceeding our previously disclosed revenue guidance while finding ways to continue to provide the highest quality services and to protect our patients, employees and physician partners.

Despite the challenging operating environment imposed by COVID-19 pandemic, we showed a resilient performance and sustained strong year-over-year revenue growth. With access to TMS therapy now more essential than ever, we have increased efforts to expand patient interactions virtually and the corresponding increased usage of these platforms by both patients and physicians contribute to this positive result. COVID-19 forced us to adapt and innovate. We expect our learning and experience through these times to provide valuable lessons and strong leverage as we continue to focus on expanding our base of clinics.

Quarterly consolidated revenue for Q2 2020 increased by 21% to $9.8 million as compared to Q2 2019, significantly exceeding our previously disclosed guidance. On a year-to-date 2020 basis, consolidated revenue increased by 44% to $21.2 million. Furthermore, Q2 2020 consolidated revenue of $9.8 million represented a decrease of only 14% as compared to Q1 2020, again, significantly exceeding our previously disclosed guidance.

We added 3 active TMS Centers during Q2 2020 with an additional 12 TMS Centers in development. This brings our total network to 125 Greenbrook Centers, which is an increase of 62% from Q2 2019. We're also particularly proud of our ability to reach new patients during this difficult time. In June, we established a record monthly high and new patient treatment starts, which supports a strong upward trend following the initial impact of COVID-19 and position us well for what we hope to be a strong Q3 and beyond.

And now for a more detailed review of the company's financial and operating performance, I will turn it over to our CFO, Erns Loubser.

--------------------------------------------------------------------------------

Erns Loubser, Greenbrook TMS Inc. - CFO, Treasurer & Corporate Secretary [3]

--------------------------------------------------------------------------------

Thank you, Bill. As Bill mentioned, despite the impact of COVID-19, consolidated quarterly revenue increased by 21% to $9.8 million in Q2 2020. On a year-to-date basis, consolidated revenue increased by 44% to $21.2 million. Furthermore, Q2 2020 consolidated revenue represented a decrease of only 14% as compared to Q1 2020. This positive result was primarily attributable to the increased efforts to provide greater access to patients virtually, through the expanded use of online platforms and focused marketing efforts on the safety and accessibility of our TMS Centers. The continued development of our TMS Center network by adding 3 active TMS Centers coupled with the Achieve TMS acquisition, also contributed to the strong growth. COVID-19 has increased demand for mental health services, including an increase in psychiatric visitors -- visits and depression and anxiety scripts, which we believe will continue to promote growth as operating conditions normalize.

As expected, same-region sales growth was negative 19% in Q2 2020, but remained positive at 2% on a year-to-date basis. The negative growth experienced in Q2 2020 was directly attributable to the impact of COVID-19. As operating conditions continue to normalize, we believe this metric will revert back to the pre-COVID-19 levels. Average revenue per treatment increased by 5% to $230 in Q2 2020 and by 5% to $234 during the year-to-date 2020 period. This increase was predominantly attributable to an increase in reimbursement rates from certain players with which we've had long-standing relationships in our established regions, and its expansion to more favorable reimbursement jurisdictions.

Moving to regional operating income. In line with our expectations, we incurred a regional operating loss for Q2 2020 of $200,000 as compared to regional operating income of $1 million in Q2 2019. Regional operating income decreased 68% to $500,000 during the year-to-date period 2020. This is from a prior -- this is attributable to a reduction in patient treatments during the period as a result of COVID-19. The regional operating income margin was 2.4% in year-to-date 2020 compared to 11.1% year-to-date 2019, again, due to the impact of COVID-19. Year-over-year corporate -- aggregate corporate costs increased by only 9% to $3.1 million for Q2 2020 and by 35% to $7 million on a year-to-date basis 2020. Quarter-over-quarter aggregate corporate costs, however, decreased by 19% or $750,000 compared to Q1 2020, really illustrating the success of our cost mitigation strategies.

The modest year-over-year increase in corporate G&A and decrease quarter-over-quarter, respectively, is a result of the investment in our business infrastructure and increased staffing of our shared services function in fiscal 2019, coupled with the Achieve TMS acquisition, again, offset significantly by disciplined measures implemented to control costs as a result of COVID-19.

As anticipated, the Q2 2020 and year-to-date 2020 aggregate corporate costs growth rate has decreased significantly as compared to the fiscal 2019, as we continue to scale into our centralized business infrastructure. This is further highlighted by the growth in revenue eclipsing the growth rate in aggregate corporate cost in both Q2 2020 and on a year-to-date 2022 basis. The loss for the period increased predominantly as a result for the earnout -- of the earnout payable to the sellers of Achieve TMS, which demonstrates the strong performance even during these challenging times by that business.

From a balance sheet perspective, accounts receivable increased by 0 -- by $800,000 to $10.9 million in Q2 2020 compared to Q4 2019 and decreased by $100,000 compared to Q1 2020. The company has already started to realize the benefits of the recent enhancements made to the billing and reimbursement system. This is despite the continued number of new TMS Centers with effects of payer contracting and billing system setup impacts to normal cash conversion cycle. And slightly slower reimbursement time lines experienced from payers due to the disruption caused by COVID-19. We expect accounts receivable to continue to stabilize throughout fiscal 2020.

As of Q2 2020, we had approximately $13.6 million in cash on hand, including an unsecured loan of approximately $3.1 million under the United States Paycheck Protection Program received during the quarter. We also completed a public offering of common shares for an aggregate gross proceeds of approximately CAD 15 million during the quarter. The company is using the net proceeds from the offering to fund operating activities and for other working capital and general corporate purposes, effectively strengthening our balance sheet in this current uncertain economic environment.

Moving to our core operating metrics. As of the end of Q2 2020, the total number of TMS Centers increased by 62% to 125 from 77 a year ago. Of the 125, currently, 113 centers are active and contributing to revenue. The number of consultations performed increased by 7% to 2,075 compared to Q2 2019. We increased the number of TMS treatments performed by 16% to 42,581 over Q2 2019. Patient starts increased by 22% to 1,218 compared to Q2 2019.

Our forward-looking indicators were all skewed down as a result of COVID-19 experienced during the quarter. As Bill mentioned earlier, however, we have seen a positive sentiment towards the end of the quarter, established a record monthly high in new patient start in June, which supports a strong upward trend and which we believe will position us well for the next quarter and beyond.

Back to you, Bill.

--------------------------------------------------------------------------------

Bill Leonard, Greenbrook TMS Inc. - President, CEO & Director [4]

--------------------------------------------------------------------------------

Thanks, Erns. As we mentioned earlier, we have demonstrated our ability to navigate and grow during the challenging operating environment imposed by COVID-19. Overall, we were able to exceed previously disclosed revenue guidance while continuing to provide the highest quality services and protecting our patient, employees and physician partners. We are particularly proud of our ability to reach new patients during this difficult time, and I am confident that our business will emerge even stronger as market conditions continue to normalize. The need for mental health support is an all-time high, and despite a slowdown in development activity, our development pipeline is stronger than ever and prime for expansion when market conditions allow. We have now treated over 13,000 patients with over 460,000 treatments performed. We are closing in on 0.5 million TMS therapy treatments, a significant positive impact on the lives of so many patients suffering from depression. We look forward to keeping you updated on the progress of the company throughout 2020.

Thank you for your time today. And with that, Lindsey, we will now take questions.

================================================================================

Questions and Answers

--------------------------------------------------------------------------------

Operator [1]

--------------------------------------------------------------------------------

(Operator Instructions) Our first question comes from the line of David Newman with Desjardins.

--------------------------------------------------------------------------------

David Francis Newman, Desjardins Securities Inc., Research Division - Analyst [2]

--------------------------------------------------------------------------------

Solid results and the trends look positive. So congratulations. I just want to get a little bit more attribution though around your outlook overall. So if you had to go month by month, in terms of patient volumes, revenues, new patient starts and some of the metrics that you guys measure. How did July shape up? And how did June shape up? And how did this kind of trend month-by-month through the quarter? Just so we get a better sense of your optimism for the third quarter, which obviously is looking pretty decent.

--------------------------------------------------------------------------------

Bill Leonard, Greenbrook TMS Inc. - President, CEO & Director [3]

--------------------------------------------------------------------------------

Yes, great question, David. I think from our perspective, when Q2 started, the initial impact of the pandemic was felt late March and then into the start of Q2 in April. From that point, we did several key items operationally that really helped us start to trend up. I think the first thing we did was really from a marketing perspective was to really get the message out on what shelter-in-place and stay-at-home government mandate meant. We did a great job with utilizing platforms such as TV and news radio to make sure patients understood the need for care of their mental health indications. That was the first thing. Allowing us to utilize the platform virtually really created patients the opportunity to get to us without having to have multiple trips to the center. And then really, we start to see a significant impact and rise in our treatments and new patient starts from really May and then into a record-breaking June. Obviously, I can't speak a lot about July, but I will tell you that I don't believe June will be our forever high watermark for the company for the year.

--------------------------------------------------------------------------------

David Francis Newman, Desjardins Securities Inc., Research Division - Analyst [4]

--------------------------------------------------------------------------------

Okay. And do you think you -- as you look out, do you think you could -- it sounds like you could, but I just want to hear your thoughts on it. But do you think you could exceed pre COVID level run rates?

--------------------------------------------------------------------------------

Bill Leonard, Greenbrook TMS Inc. - President, CEO & Director [5]

--------------------------------------------------------------------------------

Yes. I mean I continue to see positive trends. I think we are still in the midst of the pandemic, with hotspots popping up throughout the U.S. With that said, there's a different sentiment right now. I think patients were really confused early on the whole government mandates of stay-at-home and shelter-in-place. I think now you're seeing an increase in depression scripts written, you're seeing an increase in psychiatric visits. We've seen numbers of 20% to 30% of new scripts written, which really builds a pipeline for us in the future months ahead. So obviously, I do think the company will continue to grow, as we stated earlier. I think we are in a great position as an organization to take advantage of, unfortunately, the growth in mental health needs. So we feel really confident about the position we're in and expect to see growth in the months to come.

--------------------------------------------------------------------------------

David Francis Newman, Desjardins Securities Inc., Research Division - Analyst [6]

--------------------------------------------------------------------------------

All right, Bill. And then Bill, if you look out, I think your target -- initial target was like 140 centers by the end of this year. And you're not about far off, to be honest. And you've got about 18 months of capital for OpEx and CapEx. I mean how are you thinking about center expansion again? If you're seeing this kind of activity level. So what are you guys thinking in terms of that, in terms of expansion?

--------------------------------------------------------------------------------

Bill Leonard, Greenbrook TMS Inc. - President, CEO & Director [7]

--------------------------------------------------------------------------------

Yes. We are still focused on being a growth company. We are really kind of making sure that the trends continue to kind of move upwards. And as far as growth is concerned, like I said earlier, our pipeline has gotten better. One thing COVID did do was create a really strong pipeline for us. We continue to explore opportunities and at the right time, we'll kind of get back on the development train, which we hope to be late this year into Q1.

--------------------------------------------------------------------------------

David Francis Newman, Desjardins Securities Inc., Research Division - Analyst [8]

--------------------------------------------------------------------------------

Very good. And the last one for me, guys. Just on the cost cutting efforts, obviously, you did a lot of good things here in terms of your ability to cut costs, including furloughing some employees which are now coming back. And any of the savings that you're -- that you might believe could become more permanent? Often, these are opportunities to come along where -- I mean that COVID is not really an opportunity, but it does allow you to sort of look in the mirror and kind of look at your cost structure and find inefficiencies, and you did cite that you're around USD 1.2 million in discretionary expenses realized. I assume that's an annualized number towards your $2 million target. But anything that could be -- as we're looking to sort of forecasting our cost structure going out, any that's going to be more permanent in nature?

--------------------------------------------------------------------------------

Erns Loubser, Greenbrook TMS Inc. - CFO, Treasurer & Corporate Secretary [9]

--------------------------------------------------------------------------------

I think we certainly, as we mentioned, what COVID-19 did, it forced us to innovate. And also, as you mentioned, forced us to look at kind of our cost structure and the optimal cost structure. So I think there's certainly lessons learned how we managed to fairly rapidly take costs out of the cost structure from Q1 to Q2, a $750,000 reduction. So I think there is opportunity and some lessons learned that we can rationalize that and learn going forward as it relates to, for instance, marketing expenses to keep the business even leaner than it was before.

--------------------------------------------------------------------------------

David Francis Newman, Desjardins Securities Inc., Research Division - Analyst [10]

--------------------------------------------------------------------------------

And, Erns. Was that -- was the $750,000, was that actually out of the income statement? Or is that an annualized number?

--------------------------------------------------------------------------------

Erns Loubser, Greenbrook TMS Inc. - CFO, Treasurer & Corporate Secretary [11]

--------------------------------------------------------------------------------

That was actually -- so we had about $3.8 million in corporate G&A in Q1, and we came in about a $3.1 million in -- just below $3.1 million in Q2. So that was actual cost cuts based on kind of our Q1 run rate to our Q2.

--------------------------------------------------------------------------------

Operator [12]

--------------------------------------------------------------------------------

Our next question comes from the line of Noel Atkinson with Clarus Securities.

--------------------------------------------------------------------------------

Noel John Atkinson, Clarus Securities Inc., Research Division - VP & Research Analyst of Growth and Innovation [13]

--------------------------------------------------------------------------------

Well done in Q2. I wanted to get your insight about Neuronetics. So they've announced recently some significant improvements in TMS therapy eligibility with several major insurers. And I just wanted to see how you think that flows through to hopefully benefiting Greenbrook?

--------------------------------------------------------------------------------

Bill Leonard, Greenbrook TMS Inc. - President, CEO & Director [14]

--------------------------------------------------------------------------------

Yes. We appreciate and applaud the work Neuronetics did to continue to expand accessibility for TMS therapy. As it relates to their announcement yesterday, to me, what I think you're seeing now is the momentum driving as with TMS therapy is close to first-line treatment as possible when you're getting down to 1 to 2 failed cycles of med, compared to when we started, where in 2013, '17, it was 4 to 6 cycles of meds. So I think now that the payers are seeing the results of TMS therapy and the need to support depression modalities, I think you're seeing positive movement. With that said, to me, what I loved about it was the fact that demographically, it opens up the opportunity for us to treat younger patients. Some of the patients in that 18 to 21 range, 22, 23, have not been on 4 or 5 cycles of meds yet. They've only been on 1 or 2, so it allows you to get to that demographic, that younger patient population sooner as opposed to later. There is a lag period. I think, for every 1 or 2 trials you make, it's probably a 6th month lag. So I do think it helps increase the pipeline and expand the demographics late fall -- late winter, early spring for Greenbrook. And we're in a great position to take advantage of it, not only with our footprint, but with our growth. And obviously, we have great doctors and a great patient experience.

--------------------------------------------------------------------------------

Noel John Atkinson, Clarus Securities Inc., Research Division - VP & Research Analyst of Growth and Innovation [15]

--------------------------------------------------------------------------------

Okay. Great. This might have been asked already, I apologize, I had to step off for a sec. But are you negotiating with any of your landlords in terms of rent forbearance or deferrals or anything like that?

--------------------------------------------------------------------------------

Bill Leonard, Greenbrook TMS Inc. - President, CEO & Director [16]

--------------------------------------------------------------------------------

I wouldn't say we're negotiating because unlike some businesses, we actually have been open and seeing patients. We have not closed any of our centers down. So our patients are actively coming to our centers on a day-to-day basis. So it would be difficult for us to negotiate kind of abatement when we are still actively using those centers, which is a good thing as we stayed open during this pandemic.

--------------------------------------------------------------------------------

Noel John Atkinson, Clarus Securities Inc., Research Division - VP & Research Analyst of Growth and Innovation [17]

Original post:

Edited Transcript of GTMS.TO earnings conference call or presentation 5-Aug-20 2:00pm GMT - Yahoo Finance

Rivers on ancient Mars may have flowed beneath sheets of ice – Astronomy Magazine

Posted on August 8, 2020 by Danzig

The evidence that water once existed on Mars is unmistakable: The planet is covered in valleys that appear carved by flowing water. For decades, these epic ravines and branching riverbeds beckoned planetary scientists to imagine a 3.5-billion-year-old world that was both warm and wet, covered with lakes and rivers possibly hosting an environment conducive to life.

But new research suggests Mars might not have been the balmy paradise scientists once envisioned. Now, the evidence seems to suggest that rivers may not have covered its surface, but instead flowed deep under large sheets of ice.

To come to this conclusion, the researchers performed a statistical analysis of the shapes and patterns of 66 networks of valleys on Mars, which are composed of over 10,000 individual valleys. They then compared these to similar features on Earth.

They found that 14 of the martian sites appeared to have characteristics reminiscent of above-ground rivers. But 31 seemed to be carved out by either glacial or subglacial meltwater, more like terrain found near former glaciers on Earth.

See the original post here:

Rivers on ancient Mars may have flowed beneath sheets of ice - Astronomy Magazine

Futurist Transhuman News Blog

Author Archives: Danzig

Aerospace Nanotechnology Market Current Trends, Swot Analysis, Business Overview and Forecast by 2028 | Key Players: Airbus, Glonatech, Flight Shield,…

How studying genetics and lifestyle can shape a healthier MENA region – The European Sting

Immatics Extends Cell Therapy Manufacturing Collaboration with UTHealth – marketscreener.com

New Report: Regenerative Medicine & Advanced Therapies Sector Thriving Despite COVID-19 – GlobeNewswire

Impact of COVID-19 Outbreak on Canine Stem Cell Therapy Market Expected to Secure Notable Revenue Share During 2020-2026 – Research Newspaper

UK housing is on the agenda. How do we really build back better? – Big Issue

Calyxt will license its plant gene-editing tech to other firms – Minneapolis Star Tribune

JinkoSolar reshapes PV technology scenarios with its new N-Type Tiger Pro 610W unveiled at SNEC 2020 – PRNewswire

By Next Year, Will Doctors Finally Have The Technology To Fully Personalize Treatments For Lung Cancer Patients? – Forbes

BMW launches its world-first eDrive Zones technology in the UK – Automotive World

What is China’s New Infrastructure Plan and Will it Benefit Tech Investors? – China Briefing

Another Life: Our second ash comes into conflict with technology – The Irish Times

Not just a fad, cloud provides the foundation for future technologies – Federal News Network

Bodle Technologies announces world’s first TFT driven Solid State Reflective Display fabricated on a GEN2.5 line – Digital Signage Connection

Color Star Technology Announces Machine Gun Kelly will join its "Fearless, Color World" Online Concert – PRNewswire

5G and Cloud Computing Technologies Market Report, History and Forecast 2020-2026, Breakdown Data by Manufacturers, Key Regions, Types and Application…

World TMS (Transcranial Magnetic Stimulation) Coil Market Industry: A Latest Research Report to Share Market Insights and Dynamics – Bulletin Line

TMS Webinar puts the spotlight on Offshore Oil and Gas – Latest Maritime & Shipping News Online – The Maritime Standard

Edited Transcript of GTMS.TO earnings conference call or presentation 5-Aug-20 2:00pm GMT – Yahoo Finance

Rivers on ancient Mars may have flowed beneath sheets of ice – Astronomy Magazine